|
|
||||||||
|
|
|||||||||
|
|
Radiopharmaceutical Chemistry: New Chemistry-OncologyNew Chemistry-Oncology Posters |
1 Molecular Insight Pharmaceuticals, Cambridge, Massachusetts
1236
Objectives: Synthesize and evaluate novel glutamate-urea (Glu-urea-X) heterodimers to develop a structure activity relationship (SAR) for small molecule inhibitors of PSMA as radiotracers for the detection of prostate cancer.
Methods: The Glu-Urea-Lys moiety was employed as a building block for the synthesis of a series of Glu-urea-X heterodimers where X =
-N-(o-I, m-I, p-I, , p-Br, o-Cl, m-Cl, p-Cl, p-F, H)-benzyl-Lys and
-(p-I, p-Br, p-Cl, H)-phenyl ureido-Lys. The compounds were prepared by reaction of the free amine of the protected Glu-urea-Lys intermediate with the appropriate phenylisocyanates or via reductive alkylation with the desired substituted benzaldehyde derivatives. The affinities were determined by screening in a competitive binding assay.
Results: Overall synthetic yields ranged from 20-60%. The benzyl lysine series showed a clear relationship between the nature of the halogen substituent and PSMA binding affinity. In the para substituted series the IC50 values followed the trend Cl >I = Br > >F = H. In addition, the binding affinity was influenced by the position of the halogen atom on the aryl ring (IC50 values p-I > o-I>> m-I). The nature of the halogen atom had little effect on the binding affinity in the para substituted phenylureido-Lys series (IC50 values Cl = I = Br = F = H).
Conclusions: An SAR was established for two series of Glu-urea-X heterodimers by systematically substituting halogen atoms on the aryl ring. These data have led to the development of clinical candidates for the detection of prostate cancer.
| ||||||||||||||||||||||||||||||||||||||